Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1992 1
1997 2
1998 1
1999 4
2000 5
2001 4
2002 6
2003 7
2004 6
2005 10
2006 9
2007 7
2008 11
2009 10
2010 19
2011 15
2012 19
2013 17
2014 19
2015 12
2016 14
2017 21
2018 20
2019 19
2020 37
2021 35
2022 26
2023 22
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Results by year

Filters applied: . Clear all
Page 1
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer S, Linardic CM, Kelsey A, Rudzinski ER, Vokuhl C, Selfe J, Ruhen O, Shern JF, Khan J, Kovach AR, Lupo PJ, Gatz SA, Schäfer BW, Volchenboum S, Minard-Colin V, Koscielniak E, Hawkins DS, Bisogno G, Sparber-Sauer M, Venkatramani R, Merks JHM, Shipley J. Hettmer S, et al. Among authors: bisogno g. Eur J Cancer. 2022 Sep;172:367-386. doi: 10.1016/j.ejca.2022.05.036. Epub 2022 Jul 12. Eur J Cancer. 2022. PMID: 35839732 Free article. Review.
Maintenance Chemotherapy for Patients with Rhabdomyosarcoma.
Bisogno G, Minard-Colin V, Jenney M, Ferrari A, Chisholm J, Di Carlo D, Hjalgrim LL, Orbach D, Merks JHM, Casanova M. Bisogno G, et al. Cancers (Basel). 2023 Aug 7;15(15):4012. doi: 10.3390/cancers15154012. Cancers (Basel). 2023. PMID: 37568826 Free PMC article. Review.
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Bisogno G, De Salvo GL, Bergeron C, Gallego Melcón S, Merks JH, Kelsey A, Martelli H, Minard-Colin V, Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben-Arush M, Mudry P, Ferman S, Jenney M, Ferrari A; European paediatric Soft tissue sarcoma Study Group. Bisogno G, et al. Lancet Oncol. 2019 Nov;20(11):1566-1575. doi: 10.1016/S1470-2045(19)30617-5. Epub 2019 Sep 24. Lancet Oncol. 2019. PMID: 31562043 Clinical Trial.
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, Gallego Melcon S, Gatz SA, Le Deley MC, McHugh K, Probst A, Rocourt N, van Rijn RR, Wheatley K, Minard-Colin V, Chisholm JC. Defachelles AS, et al. Among authors: bisogno g. J Clin Oncol. 2021 Sep 20;39(27):2979-2990. doi: 10.1200/JCO.21.00124. Epub 2021 Aug 3. J Clin Oncol. 2021. PMID: 34343032 Clinical Trial.
Alveolar Rhabdomyosarcoma Decellularization.
Pozzobon M, Saggioro M, D'Agostino S, Bisogno G, Muraca M, Gamba P. Pozzobon M, et al. Among authors: bisogno g. Methods Mol Biol. 2018;1577:317-325. doi: 10.1007/7651_2017_45. Methods Mol Biol. 2018. PMID: 28540560
A joint international consensus statement for measuring quality of survival for patients with childhood cancer.
van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. van Kalsbeek RJ, et al. Nat Med. 2023 Jun;29(6):1340-1348. doi: 10.1038/s41591-023-02339-y. Epub 2023 Jun 15. Nat Med. 2023. PMID: 37322119 Review.
Joining forces for pediatric very rare tumors.
Ferrari A, Schneider DT, Bisogno G, Trama A. Ferrari A, et al. Among authors: bisogno g. Oncotarget. 2019 May 3;10(33):3084-3085. doi: 10.18632/oncotarget.26871. eCollection 2019 May 3. Oncotarget. 2019. PMID: 31139319 Free PMC article. No abstract available.
Biological Role and Clinical Implications of MYOD1L122R Mutation in Rhabdomyosarcoma.
Di Carlo D, Chisholm J, Kelsey A, Alaggio R, Bisogno G, Minard-Colin V, Jenney M, Dávila Fajardo R, Merks JHM, Shipley JM, Selfe JL. Di Carlo D, et al. Among authors: bisogno g. Cancers (Basel). 2023 Mar 7;15(6):1644. doi: 10.3390/cancers15061644. Cancers (Basel). 2023. PMID: 36980529 Free PMC article. Review.
Carcinoma and Sarcoma Microenvironment at a Glance: Where We Are.
Saggioro M, D'Angelo E, Bisogno G, Agostini M, Pozzobon M. Saggioro M, et al. Among authors: bisogno g. Front Oncol. 2020 Mar 3;10:76. doi: 10.3389/fonc.2020.00076. eCollection 2020. Front Oncol. 2020. PMID: 32195166 Free PMC article. Review.
Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study.
Bisogno G, Minard-Colin V, Zanetti I, Ferrari A, Gallego S, Dávila Fajardo R, Mandeville H, Kelsey A, Alaggio R, Orbach D, Terwisscha van Scheltinga S, Guillén Burrieza G, Ben-Arush M, Glosli H, Mudry P, Ferman S, Devalck C, Defachelles AS, Merks JHM, Jenney M. Bisogno G, et al. J Clin Oncol. 2023 May 1;41(13):2342-2349. doi: 10.1200/JCO.22.02093. Epub 2023 Feb 27. J Clin Oncol. 2023. PMID: 36848614 Clinical Trial.
337 results